- A meta-analysis of randomized controlled trials (RCTs), including MONALEESA, MONARCH, and PALOMA, erases any doubt about the benefits of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors when combined with endocrine therapy (ET) for treatment of hormone receptor (HR)-positive/human epidermal growth factor receptor-2 (HER2)-negative advanced breast cancer (aBCa).
- CDK4/6 inhibitor+ET showed superior OS, PFS, objective response rate (ORR), and clinical benefit rate (CBR) compared with ET alone.
Why this matters
- CDK4/6 inhibitor combined with ET should be considered the preferred treatment option for HR+/HER2− aBCa.
- A meta-analysis of 8 RCTs (N=4580) after search including PubMed, MEDLINE, Cochrane Central Register, and EMBASE.
- Funding: None.
- CDK4/6 inhibitor+ET vs ET alone was superior for:
- PFS: HR, 0.55 (P<.00001>
- OS: HR, 0.79 (P=.004).
- ORR: risk ratio (RR), 1.47 (P<.00001>
- CBR: RR, 1.20 (P<.00001>
- Heterogeneity across studies.